A Chicago startup that makes software that helps life sciences companies bring their drugs, vaccines and medical devices to market faster has raised more funding to grow its business.
Vodori announced that it has raised a $7.5 million Series A round led by Chicago-based Baird Capital, the venture capital and private equity arm of Milwaukee-based Robert W. Baird & Co. The startup raised a $3 million seed round in 2020.
Founded in 2005, Vodori makes sales enablement and analytics software for biotech firms, along with content review, approval and compliance solutions. Its tech helps automate the process for life science companies to get their content and products to patients and health care providers.
"We've been extremely impressed by Vodori's intuitive and flexible suite of cloud-based solutions and look forward to leveraging our firm’s deep expertise and network in the life sciences and B2B software sectors to support the company in its next phase of growth," said Jim Pavlik, partner with Baird Capital’s Venture Capital team.
Pavlik will join the board of directors at Vodori, alongside existing directors Brian Parker, Jim Hussey, Richard Gochnauer and Scott Rovegno, who is founder and CEO of Vodori.
The company says it has customers in 50 countries, counting pharma, biotech and medical device companies among its clients.
Vodori's customers include Biocartis, Progenity, Tris Pharma and Generate Life Sciences.
Rovegno said in a statement that Vodori aims to "make it easy for life science companies to move fast and get critical care to those who need it most.”
"Our long track record in life sciences makes us acutely aware of the fact that health care can’t wait," he said.
